Fact CheckerSign in

NCT04762992Enrolling by invitationPhase 3

LMWH for Treatment of Early Fetal Growth Restriction (HepaGrowth)

Low Molecular Weight Heparin for the Treatment of Early Fetal Growth Restriction

Source: ClinicalTrials.gov · Last updated 13 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Early fetal growth restriction (FGR) is associated with considerable fetal and neonatal morbimortality. Placental thrombosis, infarcts and hypercoagulability are frequently seen in these pregnancies, suggesting a role for the activation of the coagulation cascade in the genesis of FGR. Patients will be randomized for low-molecular weight heparin or standard of care, and the outcomes of both arms (gestational age at delivery, gestational and fetal morbidity) will be compared.

Status (registry)
Enrolling by invitation
Phase (registry)
Phase 3
Study type
Interventional
Enrollment
12 (estimated)
First submitted
17 Feb 2021
Start date
18 Jul 2022
Primary completion date
30 Jul 2026
Lead sponsor
Centro Hospitalar de Lisboa Central
NCT number
NCT04762992

What you commit to

  • Study type: Interventional · Phase 3
  • Planned participants: 12
  • From 18 Jul 2022 to the primary completion date, 30 Jul 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • use of LMWH or NFH in the index pregnancy before randomization or start of any of these medications for another indication if the patient is in the control group

Other illness

  • evidence of fetal infection (serological or after invasive testing);
  • maternal history of allergy to LMWH or non-fractionated heparin (NFH);
  • hypersensitivity to pork products;
  • maternal history of heparin-induced thrombocytopenia;
  • history of maternal hemophilia or Von Willebrand disease
  • active clinically significant bleeding and conditions with a high risk of hemorrhage, including recent hemorrhagic stroke, gastrointestinal ulcer, presence of malignant neoplasm at high risk of bleeding, recent brain, spinal or ophthalmic surgery, known or suspected esophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities;
  • known or suspected hepatic impairment;

Lab values

  • maternal thrombocytopenia (platelets \< 100 000);
  • history of severe renal disease (eGFR \<30mL/min);

Other

  • multiple gestation;
  • diagnosed fetal chromosomal abnormalities;
  • associated fetal morphological malformations;
  • present use of systemic salicylates in anti-inflammatory dosage (\> 150mg/day) or NSAIDs (including ketorolac)
  • presence of placental hematoma;
  • maternal diabetic retinopathy;
  • bacterial endocarditis;
  • persistent blood pressure \> 160/100 mmHg, despite optimal anti-hypertensive regimen;
  • current participation in another clinical trial;
  • patients that are not part of the national health system (SNS);
  • delivery already scheduled, or predicted in the next 7 days.

Who the study is looking for

  • being 18 years old or older
  • being able to provide consent
  • having a viable singleton pregnancy with diagnosed early FGR confirmed in our unit according to the 2020 International Society of Ultrasound in Obstetrics \& Gynecology (ISUOG) criteria (one solitary parameter: estimated fetal weight/ abdominal circumference lower than the 3rd centile or absent end-diastolic flow in umbilical artery; or estimated fetal weight/abdominal circumference below the 10th centile combined with either umbilical artery pulsatility index \> 95th centile or uterine artery mean pulsatility index \> 95th centile)

Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Centro de Diagnóstico Pré-Natal, Maternidade Dr. Alfredo da Costa, Centro Hospitalar Universitário de Lisboa Central
Coordinator of this site? Confirm its status
LisbonPortugalUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.